Dosing & Uses
Dosage Forms & Strengths
tablet
- 50mg
Periodic Paralysis
Indicated for primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants
50 mg PO qDay or q12hr initially; increase or decrease at weekly intervals according to individual response; not to exceed 200 mg/day
Evaluate response after 2 months of treatment to decide drug should be continued
Dosing Considerations
Obtain baseline and periodic measurements of serum potassium and sodium bicarbonate
Safety and efficacy not established
Periodic Paralysis
Indicated for primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants
50 mg PO qDay or q12hr initially; increase or decrease at weekly intervals according to individual response; not to exceed 200 mg/day
Evaluate response after 2 months of treatment to decide whether drug should be continued
Use lowest effective dose possible, owing to risk increased risk of falls
Dosing Considerations
Obtain baseline and periodic measurements of serum potassium and sodium bicarbonate
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (7)
- aminosalicylic acid
dichlorphenamide increases levels of aminosalicylic acid by unknown mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported.
- aspirin
dichlorphenamide increases levels of aspirin by unknown mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported.
- aspirin rectal
dichlorphenamide increases levels of aspirin rectal by unknown mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported.
- bismuth subsalicylate
dichlorphenamide increases levels of bismuth subsalicylate by unknown mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported.
- choline magnesium trisalicylate
dichlorphenamide increases levels of choline magnesium trisalicylate by unknown mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported.
- magnesium salicylate
dichlorphenamide increases levels of magnesium salicylate by unspecified interaction mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported.
- salsalate
dichlorphenamide increases levels of salsalate by unknown mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported.
Serious - Use Alternative (2)
- metoclopramide intranasal
dichlorphenamide, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- ropeginterferon alfa 2b
ropeginterferon alfa 2b and dichlorphenamide both increase Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity.
Monitor Closely (260)
- abiraterone
dichlorphenamide and abiraterone both decrease serum potassium. Use Caution/Monitor.
- acetazolamide
dichlorphenamide and acetazolamide both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, acetazolamide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - ado-trastuzumab emtansine
dichlorphenamide and ado-trastuzumab emtansine both decrease serum potassium. Use Caution/Monitor.
- afatinib
dichlorphenamide and afatinib both decrease serum potassium. Use Caution/Monitor.
- albuterol
dichlorphenamide and albuterol both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, albuterol. Either increases levels of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - aldesleukin
dichlorphenamide, aldesleukin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- allopurinol
dichlorphenamide and allopurinol both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, allopurinol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - alvimopan
dichlorphenamide and alvimopan both decrease serum potassium. Use Caution/Monitor.
- amiloride
dichlorphenamide, amiloride. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- amlodipine
dichlorphenamide and amlodipine both decrease serum potassium. Use Caution/Monitor.
- ammonium chloride
dichlorphenamide and ammonium chloride both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, ammonium chloride. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - amphotericin B cholesteryl sulfate
dichlorphenamide and amphotericin B cholesteryl sulfate both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, amphotericin B cholesteryl sulfate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - amphotericin B deoxycholate
dichlorphenamide and amphotericin B deoxycholate both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, amphotericin B deoxycholate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - amphotericin B liposomal
dichlorphenamide and amphotericin B liposomal both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, amphotericin B liposomal. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - amphotericin B phospholipid complex
dichlorphenamide and amphotericin B phospholipid complex both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, amphotericin B phospholipid complex. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - aprepitant
dichlorphenamide and aprepitant both decrease serum potassium. Use Caution/Monitor.
- arformoterol
dichlorphenamide and arformoterol both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, arformoterol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - arginine
dichlorphenamide, arginine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- aripiprazole
dichlorphenamide and aripiprazole both decrease serum potassium. Use Caution/Monitor.
- atenolol
dichlorphenamide and atenolol both decrease serum potassium. Use Caution/Monitor.
- azacitidine
dichlorphenamide and azacitidine both decrease serum potassium. Use Caution/Monitor.
- azithromycin
dichlorphenamide and azithromycin both decrease serum potassium. Use Caution/Monitor.
- basiliximab
dichlorphenamide and basiliximab both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, basiliximab. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - belatacept
dichlorphenamide and belatacept both decrease serum potassium. Use Caution/Monitor.
- belinostat
dichlorphenamide and belinostat both decrease serum potassium. Use Caution/Monitor.
- bendamustine
dichlorphenamide and bendamustine both decrease serum potassium. Use Caution/Monitor.
- betamethasone
dichlorphenamide and betamethasone both decrease serum potassium. Use Caution/Monitor.
- betaxolol
dichlorphenamide and betaxolol both decrease serum potassium. Use Caution/Monitor.
- bevacizumab
dichlorphenamide and bevacizumab both decrease serum potassium. Use Caution/Monitor.
- bisacodyl
dichlorphenamide and bisacodyl both decrease serum potassium. Use Caution/Monitor.
- bisoprolol
dichlorphenamide and bisoprolol both decrease serum potassium. Use Caution/Monitor.
- blinatumomab
dichlorphenamide and blinatumomab both decrease serum potassium. Use Caution/Monitor.
- bortezomib
dichlorphenamide and bortezomib both decrease serum potassium. Use Caution/Monitor.
- budesonide
dichlorphenamide and budesonide both decrease serum potassium. Use Caution/Monitor.
- bumetanide
dichlorphenamide and bumetanide both decrease serum potassium. Use Caution/Monitor.
- busulfan
dichlorphenamide and busulfan both decrease serum potassium. Use Caution/Monitor.
- cabozantinib
dichlorphenamide and cabozantinib both decrease serum potassium. Use Caution/Monitor.
- capecitabine
dichlorphenamide and capecitabine both decrease serum potassium. Use Caution/Monitor.
- capreomycin
dichlorphenamide and capreomycin both decrease serum potassium. Use Caution/Monitor.
- carboplatin
dichlorphenamide and carboplatin both decrease serum potassium. Use Caution/Monitor.
- carfilzomib
dichlorphenamide and carfilzomib both decrease serum potassium. Use Caution/Monitor.
- carmustine
dichlorphenamide and carmustine both decrease serum potassium. Use Caution/Monitor.
- carvedilol
dichlorphenamide and carvedilol both decrease serum potassium. Use Caution/Monitor.
- caspofungin
dichlorphenamide and caspofungin both decrease serum potassium. Use Caution/Monitor.
- ceftaroline
dichlorphenamide and ceftaroline both decrease serum potassium. Use Caution/Monitor.
- celecoxib
dichlorphenamide and celecoxib both decrease serum potassium. Use Caution/Monitor.
- cenobamate
cenobamate, dichlorphenamide. Either increases effects of the other by sedation. Use Caution/Monitor.
- cetuximab
dichlorphenamide and cetuximab both decrease serum potassium. Use Caution/Monitor.
- cevimeline
dichlorphenamide and cevimeline both decrease serum potassium. Use Caution/Monitor.
- chlorothiazide
dichlorphenamide and chlorothiazide both decrease serum potassium. Use Caution/Monitor.
- chlorthalidone
dichlorphenamide and chlorthalidone both decrease serum potassium. Use Caution/Monitor.
- cidofovir
dichlorphenamide and cidofovir both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, cidofovir. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - ciprofloxacin
dichlorphenamide and ciprofloxacin both decrease serum potassium. Use Caution/Monitor.
- cisplatin
dichlorphenamide and cisplatin both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, cisplatin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - citalopram
dichlorphenamide and citalopram both decrease serum potassium. Use Caution/Monitor.
- clomipramine
dichlorphenamide and clomipramine both decrease serum potassium. Use Caution/Monitor.
- conivaptan
dichlorphenamide and conivaptan both decrease serum potassium. Use Caution/Monitor.
- crizotinib
dichlorphenamide and crizotinib both decrease serum potassium. Use Caution/Monitor.
- cyanocobalamin
dichlorphenamide and cyanocobalamin both decrease serum potassium. Use Caution/Monitor.
- cytarabine
dichlorphenamide and cytarabine both decrease serum potassium. Use Caution/Monitor.
- dabrafenib
dichlorphenamide and dabrafenib both decrease serum potassium. Use Caution/Monitor.
- daridorexant
dichlorphenamide and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- dasatinib
dichlorphenamide and dasatinib both decrease serum potassium. Use Caution/Monitor.
- decitabine
dichlorphenamide and decitabine both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, decitabine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - deferiprone
dichlorphenamide, deferiprone. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- desflurane
dichlorphenamide and desflurane both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, desflurane. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - dexamethasone
dichlorphenamide and dexamethasone both decrease serum potassium. Use Caution/Monitor.
- dexlansoprazole
dichlorphenamide and dexlansoprazole both decrease serum potassium. Use Caution/Monitor.
- dexmedetomidine
dichlorphenamide and dexmedetomidine both decrease serum potassium. Use Caution/Monitor.
- dextrose (Antidote)
dichlorphenamide and dextrose (Antidote) both decrease serum potassium. Use Caution/Monitor.
- difelikefalin
difelikefalin and dichlorphenamide both increase sedation. Use Caution/Monitor.
- digoxin
dichlorphenamide and digoxin both decrease serum potassium. Use Caution/Monitor.
- dinutuximab
dichlorphenamide and dinutuximab both decrease serum potassium. Use Caution/Monitor.
- disopyramide
dichlorphenamide and disopyramide both decrease serum potassium. Use Caution/Monitor.
- dobutamine
dichlorphenamide and dobutamine both decrease serum potassium. Use Caution/Monitor.
- donepezil
dichlorphenamide and donepezil both decrease serum potassium. Use Caution/Monitor.
- doxepin
dichlorphenamide and doxepin both decrease serum potassium. Use Caution/Monitor.
- doxorubicin
dichlorphenamide and doxorubicin both decrease serum potassium. Use Caution/Monitor.
- doxorubicin liposomal
dichlorphenamide and doxorubicin liposomal both decrease serum potassium. Use Caution/Monitor.
- dronedarone
dichlorphenamide and dronedarone both decrease serum potassium. Use Caution/Monitor.
- duloxetine
dichlorphenamide and duloxetine both decrease serum potassium. Use Caution/Monitor.
- edetate calcium disodium
dichlorphenamide and edetate calcium disodium both decrease serum potassium. Use Caution/Monitor.
- epinephrine
dichlorphenamide and epinephrine both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, epinephrine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - epoetin alfa
dichlorphenamide and epoetin alfa both decrease serum potassium. Use Caution/Monitor.
- eprosartan
dichlorphenamide and eprosartan both decrease serum potassium. Use Caution/Monitor.
- eribulin
dichlorphenamide and eribulin both decrease serum potassium. Use Caution/Monitor.
- erlotinib
dichlorphenamide and erlotinib both decrease serum potassium. Use Caution/Monitor.
- ertapenem
dichlorphenamide and ertapenem both decrease serum potassium. Use Caution/Monitor.
- escitalopram
dichlorphenamide, escitalopram. sedation. Use Caution/Monitor.
- esomeprazole
dichlorphenamide and esomeprazole both decrease serum potassium. Use Caution/Monitor.
- eszopiclone
dichlorphenamide and eszopiclone both decrease serum potassium. Use Caution/Monitor.
- ethacrynic acid
dichlorphenamide and ethacrynic acid both decrease serum potassium. Use Caution/Monitor.
- etoposide
dichlorphenamide, etoposide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- everolimus
dichlorphenamide and everolimus both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, everolimus. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - febuxostat
dichlorphenamide and febuxostat both decrease serum potassium. Use Caution/Monitor.
- felbamate
dichlorphenamide and felbamate both decrease serum potassium. Use Caution/Monitor.
- fenoldopam
dichlorphenamide and fenoldopam both decrease serum potassium. Use Caution/Monitor.
- fentanyl
dichlorphenamide and fentanyl both decrease serum potassium. Use Caution/Monitor.
- fentanyl intranasal
dichlorphenamide and fentanyl intranasal both decrease serum potassium. Use Caution/Monitor.
- fentanyl transdermal
dichlorphenamide and fentanyl transdermal both decrease serum potassium. Use Caution/Monitor.
- fentanyl transmucosal
dichlorphenamide and fentanyl transmucosal both decrease serum potassium. Use Caution/Monitor.
- fidaxomicin
dichlorphenamide, fidaxomicin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- fluconazole
dichlorphenamide and fluconazole both decrease serum potassium. Use Caution/Monitor.
- flucytosine
dichlorphenamide and flucytosine both decrease serum potassium. Use Caution/Monitor.
- fludarabine
dichlorphenamide, fludarabine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- fludrocortisone
dichlorphenamide and fludrocortisone both decrease serum potassium. Use Caution/Monitor.
- fluoxetine
dichlorphenamide and fluoxetine both decrease serum potassium. Use Caution/Monitor.
- fluvoxamine
dichlorphenamide and fluvoxamine both decrease serum potassium. Use Caution/Monitor.
- fondaparinux
dichlorphenamide and fondaparinux both decrease serum potassium. Use Caution/Monitor.
- formoterol
dichlorphenamide and formoterol both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, formoterol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - fosaprepitant
dichlorphenamide and fosaprepitant both decrease serum potassium. Use Caution/Monitor.
- foscarnet
dichlorphenamide and foscarnet both decrease serum potassium. Use Caution/Monitor.
- fosphenytoin
dichlorphenamide and fosphenytoin both decrease serum potassium. Use Caution/Monitor.
- furosemide
dichlorphenamide and furosemide both decrease serum potassium. Use Caution/Monitor.
- galantamine
dichlorphenamide and galantamine both decrease serum potassium. Use Caution/Monitor.
- ganciclovir
dichlorphenamide and ganciclovir both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, ganciclovir. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - gemcitabine
dichlorphenamide and gemcitabine both decrease serum potassium. Use Caution/Monitor.
- gemifloxacin
dichlorphenamide and gemifloxacin both decrease serum potassium. Use Caution/Monitor.
- gentamicin
dichlorphenamide and gentamicin both decrease serum potassium. Use Caution/Monitor.
- glucagon intranasal
dichlorphenamide and glucagon intranasal both decrease serum potassium. Use Caution/Monitor.
- hetastarch
dichlorphenamide, hetastarch. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- hydrochlorothiazide
dichlorphenamide and hydrochlorothiazide both decrease serum potassium. Use Caution/Monitor.
- hydrocodone
dichlorphenamide and hydrocodone both decrease serum potassium. Use Caution/Monitor.
- hydrocortisone
dichlorphenamide and hydrocortisone both decrease serum potassium. Use Caution/Monitor.
- hydromorphone
dichlorphenamide and hydromorphone both decrease serum potassium. Use Caution/Monitor.
- hydroxyurea
dichlorphenamide, hydroxyurea. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- ibuprofen
dichlorphenamide, ibuprofen. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- ibuprofen IV
dichlorphenamide, ibuprofen IV. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- ifosfamide
dichlorphenamide and ifosfamide both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, ifosfamide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - iloperidone
dichlorphenamide and iloperidone both decrease serum potassium. Use Caution/Monitor.
- imatinib
dichlorphenamide and imatinib both decrease serum potassium. Use Caution/Monitor.
- indacaterol, inhaled
dichlorphenamide and indacaterol, inhaled both decrease serum potassium. Use Caution/Monitor.
- indapamide
dichlorphenamide and indapamide both decrease serum potassium. Use Caution/Monitor.
- insulin aspart
dichlorphenamide and insulin aspart both decrease serum potassium. Use Caution/Monitor.
- insulin degludec
dichlorphenamide and insulin degludec both decrease serum potassium. Use Caution/Monitor.
- insulin degludec/insulin aspart
dichlorphenamide and insulin degludec/insulin aspart both decrease serum potassium. Use Caution/Monitor.
- insulin detemir
dichlorphenamide and insulin detemir both decrease serum potassium. Use Caution/Monitor.
- insulin glargine
dichlorphenamide and insulin glargine both decrease serum potassium. Use Caution/Monitor.
- insulin glulisine
dichlorphenamide and insulin glulisine both decrease serum potassium. Use Caution/Monitor.
- insulin inhaled
dichlorphenamide and insulin inhaled both decrease serum potassium. Use Caution/Monitor.
- insulin lispro
dichlorphenamide and insulin lispro both decrease serum potassium. Use Caution/Monitor.
- insulin NPH
dichlorphenamide and insulin NPH both decrease serum potassium. Use Caution/Monitor.
- insulin regular human
dichlorphenamide and insulin regular human both decrease serum potassium. Use Caution/Monitor.
- interferon gamma 1b
dichlorphenamide and interferon gamma 1b both decrease serum potassium. Use Caution/Monitor.
- irinotecan
dichlorphenamide and irinotecan both decrease serum potassium. Use Caution/Monitor.
- isoniazid
dichlorphenamide, isoniazid. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- isosorbide mononitrate
dichlorphenamide and isosorbide mononitrate both decrease serum potassium. Use Caution/Monitor.
- ixabepilone
dichlorphenamide and ixabepilone both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, ixabepilone. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - lactulose
dichlorphenamide and lactulose both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, lactulose. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - leflunomide
dichlorphenamide and leflunomide both decrease serum potassium. Use Caution/Monitor.
- lenalidomide
dichlorphenamide and lenalidomide both decrease serum potassium. Use Caution/Monitor.
- lenvatinib
dichlorphenamide and lenvatinib both decrease serum potassium. Use Caution/Monitor.
- leuprolide
dichlorphenamide and leuprolide both decrease serum potassium. Use Caution/Monitor.
- levalbuterol
dichlorphenamide and levalbuterol both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, levalbuterol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - lorazepam
dichlorphenamide, lorazepam. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- mafenide
dichlorphenamide, mafenide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- magnesium sulfate
dichlorphenamide and magnesium sulfate both decrease serum potassium. Use Caution/Monitor.
- mannitol
dichlorphenamide and mannitol both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, mannitol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - meropenem
dichlorphenamide and meropenem both decrease serum potassium. Use Caution/Monitor.
- metaproterenol
dichlorphenamide and metaproterenol both decrease serum potassium. Use Caution/Monitor.
- metformin
dichlorphenamide, metformin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- methadone
dichlorphenamide and methadone both decrease serum potassium. Use Caution/Monitor.
- methazolamide
dichlorphenamide and methazolamide both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, methazolamide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - methyclothiazide
dichlorphenamide and methyclothiazide both decrease serum potassium. Use Caution/Monitor.
- methylprednisolone
dichlorphenamide and methylprednisolone both decrease serum potassium. Use Caution/Monitor.
- metolazone
dichlorphenamide and metolazone both decrease serum potassium. Use Caution/Monitor.
- micafungin
dichlorphenamide and micafungin both decrease serum potassium. Use Caution/Monitor.
- midazolam intranasal
midazolam intranasal, dichlorphenamide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.
- mifepristone
dichlorphenamide and mifepristone both decrease serum potassium. Use Caution/Monitor.
- milrinone
dichlorphenamide and milrinone both decrease serum potassium. Use Caution/Monitor.
- minocycline
dichlorphenamide, minocycline. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- mitoxantrone
dichlorphenamide and mitoxantrone both decrease serum potassium. Use Caution/Monitor.
- morphine
dichlorphenamide and morphine both decrease serum potassium. Use Caution/Monitor.
- moxifloxacin
dichlorphenamide and moxifloxacin both decrease serum potassium. Use Caution/Monitor.
- mycophenolate
dichlorphenamide and mycophenolate both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, mycophenolate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - nabumetone
dichlorphenamide and nabumetone both decrease serum potassium. Use Caution/Monitor.
- naproxen
dichlorphenamide and naproxen both decrease serum potassium. Use Caution/Monitor.
- nelarabine
dichlorphenamide and nelarabine both decrease serum potassium. Use Caution/Monitor.
- nelfinavir
dichlorphenamide, nelfinavir. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- nilotinib
dichlorphenamide and nilotinib both decrease serum potassium. Use Caution/Monitor.
- nisoldipine
dichlorphenamide and nisoldipine both decrease serum potassium. Use Caution/Monitor.
- nitric oxide gas
dichlorphenamide and nitric oxide gas both decrease serum potassium. Use Caution/Monitor.
- nitroprusside sodium
dichlorphenamide, nitroprusside sodium. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- nivolumab
dichlorphenamide and nivolumab both decrease serum potassium. Use Caution/Monitor.
- obinutuzumab
dichlorphenamide and obinutuzumab both decrease serum potassium. Use Caution/Monitor.
- olodaterol inhaled
dichlorphenamide and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.
- omeprazole
dichlorphenamide and omeprazole both decrease serum potassium. Use Caution/Monitor.
- ondansetron
dichlorphenamide and ondansetron both decrease serum potassium. Use Caution/Monitor.
- oprelvekin
dichlorphenamide and oprelvekin both decrease serum potassium. Use Caution/Monitor.
- oxcarbazepine
dichlorphenamide and oxcarbazepine both decrease serum potassium. Use Caution/Monitor.
- oxycodone
dichlorphenamide, oxycodone. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- paclitaxel
dichlorphenamide and paclitaxel both decrease serum potassium. Use Caution/Monitor.
- paclitaxel protein bound
dichlorphenamide and paclitaxel protein bound both decrease serum potassium. Use Caution/Monitor.
- palonosetron
dichlorphenamide and palonosetron both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, palonosetron. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - pamidronate
dichlorphenamide and pamidronate both decrease serum potassium. Use Caution/Monitor.
- panitumumab
dichlorphenamide and panitumumab both decrease serum potassium. Use Caution/Monitor.
- panobinostat
dichlorphenamide and panobinostat both decrease serum potassium. Use Caution/Monitor.
- paroxetine
dichlorphenamide and paroxetine both decrease serum potassium. Use Caution/Monitor.
- pasireotide
dichlorphenamide and pasireotide both decrease serum potassium. Use Caution/Monitor.
- phenelzine
dichlorphenamide, phenelzine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- phentermine
dichlorphenamide and phentermine both decrease serum potassium. Use Caution/Monitor.
- piperacillin
dichlorphenamide and piperacillin both decrease serum potassium. Use Caution/Monitor.
- polyethylene glycol & electrolytes
dichlorphenamide and polyethylene glycol & electrolytes both decrease serum potassium. Use Caution/Monitor.
- pomalidomide
dichlorphenamide and pomalidomide both decrease serum potassium. Use Caution/Monitor.
- ponatinib
dichlorphenamide and ponatinib both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, ponatinib. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - posaconazole
dichlorphenamide and posaconazole both decrease serum potassium. Use Caution/Monitor.
- potassium phosphates, IV
dichlorphenamide and potassium phosphates, IV both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, potassium phosphates, IV. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - pralatrexate
dichlorphenamide and pralatrexate both decrease serum potassium. Use Caution/Monitor.
- prednisone
dichlorphenamide and prednisone both decrease serum potassium. Use Caution/Monitor.
- propafenone
dichlorphenamide and propafenone both decrease serum potassium. Use Caution/Monitor.
- propofol
dichlorphenamide, propofol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- prothrombin complex concentrate, human
dichlorphenamide and prothrombin complex concentrate, human both decrease serum potassium. Use Caution/Monitor.
- pyridoxine
dichlorphenamide, pyridoxine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- quetiapine
dichlorphenamide and quetiapine both decrease serum potassium. Use Caution/Monitor.
- regorafenib
dichlorphenamide and regorafenib both decrease serum potassium. Use Caution/Monitor.
- riluzole
dichlorphenamide and riluzole both decrease serum potassium. Use Caution/Monitor.
- rivastigmine
dichlorphenamide and rivastigmine both decrease serum potassium. Use Caution/Monitor.
- romidepsin
dichlorphenamide and romidepsin both decrease serum potassium. Use Caution/Monitor.
- ropinirole
dichlorphenamide and ropinirole both decrease serum potassium. Use Caution/Monitor.
- salmeterol
dichlorphenamide and salmeterol both decrease serum potassium. Use Caution/Monitor.
- selegiline
dichlorphenamide and selegiline both decrease serum potassium. Use Caution/Monitor.
- senna
dichlorphenamide and senna both decrease serum potassium. Use Caution/Monitor.
- sevelamer
dichlorphenamide, sevelamer. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- sirolimus
dichlorphenamide and sirolimus both decrease serum potassium. Use Caution/Monitor.
- sodium phosphates, IV
dichlorphenamide and sodium phosphates, IV both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, sodium phosphates, IV. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - sorafenib
dichlorphenamide and sorafenib both decrease serum potassium. Use Caution/Monitor.
- sorbitol
dichlorphenamide, sorbitol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- spironolactone
dichlorphenamide, spironolactone. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- stiripentol
stiripentol, dichlorphenamide. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.
- sunitinib
dichlorphenamide and sunitinib both decrease serum potassium. Use Caution/Monitor.
- tacrolimus
dichlorphenamide and tacrolimus both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, tacrolimus. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - temsirolimus
dichlorphenamide and temsirolimus both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, temsirolimus. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - teniposide
dichlorphenamide, teniposide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- tenofovir DF
dichlorphenamide and tenofovir DF both decrease serum potassium. Use Caution/Monitor.
- terbutaline
dichlorphenamide and terbutaline both decrease serum potassium. Use Caution/Monitor.
- thalidomide
dichlorphenamide and thalidomide both decrease serum potassium. Use Caution/Monitor.
- theophylline
dichlorphenamide and theophylline both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, theophylline. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - tiagabine
dichlorphenamide and tiagabine both decrease serum potassium. Use Caution/Monitor.
- tigecycline
dichlorphenamide, tigecycline. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- tobramycin
dichlorphenamide and tobramycin both decrease serum potassium. Use Caution/Monitor.
- topiramate
dichlorphenamide and topiramate both decrease serum potassium. Use Caution/Monitor.
dichlorphenamide, topiramate. Either increases levels of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis. - torsemide
dichlorphenamide and torsemide both decrease serum potassium. Use Caution/Monitor.
- trametinib
dichlorphenamide and trametinib both decrease serum potassium. Use Caution/Monitor.
- trastuzumab deruxtecan
dichlorphenamide and trastuzumab deruxtecan both decrease serum potassium. Use Caution/Monitor.
- treprostinil
dichlorphenamide and treprostinil both decrease serum potassium. Use Caution/Monitor.
- tretinoin
dichlorphenamide, tretinoin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- triamcinolone acetonide injectable suspension
dichlorphenamide and triamcinolone acetonide injectable suspension both decrease serum potassium. Use Caution/Monitor.
- triamterene
dichlorphenamide, triamterene. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- valganciclovir
dichlorphenamide and valganciclovir both decrease serum potassium. Use Caution/Monitor.
- vancomycin
dichlorphenamide and vancomycin both decrease serum potassium. Use Caution/Monitor.
- vandetanib
dichlorphenamide and vandetanib both decrease serum potassium. Use Caution/Monitor.
- varenicline
dichlorphenamide and varenicline both decrease serum potassium. Use Caution/Monitor.
- venlafaxine
dichlorphenamide and venlafaxine both decrease serum potassium. Use Caution/Monitor.
- vismodegib
dichlorphenamide and vismodegib both decrease serum potassium. Use Caution/Monitor.
- vitamin A
dichlorphenamide, vitamin A. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
- voriconazole
dichlorphenamide and voriconazole both decrease serum potassium. Use Caution/Monitor.
- vorinostat
dichlorphenamide and vorinostat both decrease serum potassium. Use Caution/Monitor.
- ziprasidone
dichlorphenamide and ziprasidone both decrease serum potassium. Use Caution/Monitor.
- zoledronic acid
dichlorphenamide and zoledronic acid both decrease serum potassium. Use Caution/Monitor.
- zonisamide
dichlorphenamide, zonisamide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.
Minor (0)
Adverse Effects
>10%
Paresthesia (44%)
Cognitive disorder (14%)
Dysgeusia (14%)
Confusional state (11%)
1-10%
Headache (8%)
Hypoesthesia (8%)
Lethargy (8%)
Fatigue (8%)
Muscle spasms (8%)
Rash (8%)
Dizziness (6%)
Diarrhea (6%)
Nausea (6%)
Malaise (6%)
Decreased weight (6%)
Arthralgia (6%)
Muscle twitching (6%)
Dyspnea (6%)
Pharyngolaryngeal pain (6%)
Pruritus (6%)
Postmarketing Reports
Amnesia
Cardiac failure
Convulsion
Fetal death
Hallucination
Nephrolithiasis
Pancytopenia
Psychotic disorder
Renal tubular necrosis
Stupor
Syncope
Tremor
Warnings
Contraindications
Hypersensitivity to dichlorphenamide or other sulfonamides
Coadministration with high-dose aspirin
Severe pulmonary disease, limiting compensation to metabolic acidosis caused by dichlorphenamide
Hepatic insufficiency; dichlorphenamide may aggravate hepatic encephalopathy
Cautions
Fatalities associated with sulfonamides reported; hypersensitivity, anaphylaxis, and idiosyncratic reactions reported and may include Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias; pulmonary symptoms may occur in isolation or as part of a systemic reaction; discontinue at first sign of rash
Dichlorphenamide increases potassium excretion and may cause hypokalemiareported; monitor potassium levels periodically; risk is greater when used with conditions associated with hypokalemia (eg, adrenocortical insufficiency, hyperchloremic metabolic acidosis, respiratory acidosis) and in patients receiving other drugs that may cause hypokalemia; if hypokalemia develops or persists, consider dose reduction or discontinuation of drug, and correct serum potassium
Can cause hyperchloremic nonanion gap metabolic acidosis; coadministration with other drugs that cause metabolic acidosis may increase the severity; measure bicarbonate at baseline and then periodically; if metabolic acidosis develops or persists, consider reducing dose or discontinuing the drug
Increased risk of falls; risk is greater in elderly patients and with higher doses
Drug interaction overview
-
Aspirin and other salicylates
- Carbonic anhydrase inhibitors, including dichlorphenamide, can cause metabolic acidosis, which may increase salicylate toxicity
- Contraindicated with high-dose aspirin owing to risk of anorexia, tachypnea, lethargy, and coma
- Monitor carefully if coadministered with low-dose aspirin
-
OAT1 substrates
- Dichlorphenamide is an inhibitor of OAT1 transporters in vitro
- Coadministration may increase plasma exposure of OAT1 substrates
- Use with sensitive OAT1 substrates (methotrexate, famotidine, oseltamivir) is not recommended
-
OAT1/3 inhibitors
- Dichlorphenamide is a substrate of human transporters OAT1 and OAT3
- Monitor for signs of dichlorphenamide toxicity if coadministered with OAT1 or OAT3 inhibitors
-
Drug-induced hypokalemia
- Hypokalemia risk increases if coadministered with other drugs that decrease serum potassium (eg, loop diuretics, thiazide diuretics, laxatives, antifungals, penicillin, theophylline)
-
Drug-induced metabolic acidosis
- Coadministration with other drugs that cause metabolic acidosis may increase acidosis severity
Pregnancy & Lactation
Pregnancy
Data are not available on the developmental risk associated with the use in pregnant women
Animal studies
- Dichlorphenamide was teratogenic when administered orally to pregnant rats; fetal limb reduction defects observed at 17 x MRHD
Clinical considerations
- Treatment can cause metabolic acidosis
- Effect of dichlorphenamide-induced metabolic acidosis has not been studied in pregnancy; however, metabolic acidosis in pregnancy (due to other causes) can cause decreased fetal growth, decreased fetal oxygenation, and fetal death, and may affect the fetus’ ability to tolerate labor
- Monitor pregnant women for metabolic acidosis and treat as in the nonpregnant state
- Monitor newborns of mothers treated with dichlorphenamide for metabolic acidosis because of possible occurrence of transient metabolic acidosis following birth
-
Labor or delivery
- Although the effect on labor and delivery in humans has not been established, the development of dichlorphenamide-induced metabolic acidosis in the mother and/or in the fetus might affect the fetus’ ability to tolerate labor
Lactation
Unknown if distributed in human breast milk
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Carbonic anhydrase inhibitor, but the exact mechanism by which dichlorphenamide is able to treat periodic paralysis is unknown
Dichlorphenamide helps to normalize blood-potassium levels by decreasing levels
Absorption
Peak plasma time: 1.5-3 hr
Steady-state achieved: Within 10 days of twice-daily dosing
Distribution
Protein bound: 88%
Metabolism
Not a substrate of CYP isoenzymes
Elimination
Half-life: 32-66 hr
Administration
Oral Administration
May take with or without food
Storage
Store at controlled room temperature of 20-25ºC (68-77ºF)
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| dichlorphenamide oral - | 50 mg tablet |  | |
| Keveyis oral - | 50 mg tablet |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
dichlorphenamide oral
DICHLORPHENAMIDE - ORAL
(DYE-klor-FEN-a-mide)
COMMON BRAND NAME(S): Keveyis
USES: This medication is used to treat a certain inherited condition that causes attacks of muscle weakness or loss of muscle movement that come and go (primary periodic paralysis). Dichlorphenamide belongs to a class of drugs known as carbonic anhydrase inhibitors. It is not known how it works for this condition, but it can decrease the number of attacks of muscle weakness.
HOW TO USE: Take this medication by mouth as directed by your doctor, usually once or twice daily. The dosage is based on your medical condition and response to treatment.Use this medication regularly to get the most benefit from it. To help you remember, take it at the same time(s) each day.Tell your doctor if your condition does not get better or if it gets worse.
SIDE EFFECTS: Numbness/tingling, change in the sense of taste, nausea, diarrhea, weight loss, muscle spasms/twitching, tiredness, dizziness, or drowsiness may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.Dizziness can increase the risk of falling. Get up slowly when rising from a sitting or lying position.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: easy bleeding/bruising, rapid breathing, unusual tiredness, mental/mood changes (such as confusion, inability to think clearly), signs of low potassium level in the blood (such as muscle cramps, irregular heartbeat).A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before taking dichlorphenamide, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: adrenal gland problems (such as Addison's disease), liver problems, breathing problems (such as asthma, chronic obstructive lung disease-COPD).This drug may make you dizzy or drowsy. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).This medication may make you more sensitive to the sun. Limit your time in the sun. Avoid tanning booths and sunlamps. Use sunscreen and wear protective clothing when outdoors. Tell your doctor right away if you get sunburned or have skin blisters/redness.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be at greater risk for falls or low bicarbonate levels while using this drug.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this medication passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug are: aspirin (in high doses used to treat pain), salicylates, methenamine.If your doctor has directed you to take low-dose aspirin for heart attack or stroke prevention (usually 81-162 milligrams a day), you should continue taking the aspirin unless your doctor instructs you otherwise.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: shaking (tremors), ringing in the ears.
NOTES: Do not share this medication with others.Lab and/or medical tests (such as bicarbonate and potassium blood levels) should be done before you start taking this medication and while you are taking it. Keep all medical and lab appointments.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised August 2021. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
